Released Mar 28, 2024, after the close
10-K filed Mar 28, 2024, 88 days after period end · 0000950170-24-038092
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.89M$1.89M derived−22.3% vs Q4 2022−4.3% vs Q3 2023
Net Income-$458.00K-$458.00K derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$424,000N/M
Operating Cash Flowderived$161,000+103.8%
Free Cash Flowderived$161,000+103.8%
Margins · derived
Operating margin-22.4%−25.0 pt vs Q4 2022
Net margin-24.2%−25.2 pt vs Q4 2022
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.89M | $2.43M | $1.84M | $1.48M |
| Net Income | -$458.00K | $23.00K | -$351.00K | -$721.00K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
International Stem Cell CORP · CIK 1355790 · Engraved from SEC EDGAR